; (B) the Department of Veterans Affairs; (C) the National Institutes of Health; (D) the Food and Drug Administration; and (E) the Centers for Medicare & Medicaid Services; and (7) urges that the options to be considered by the Sickle Cell Disease Interagency Cabinet not only address access to potential future curative treatments, but also address the bias that those with sickle cell disease continue to face within the United States health care system.